MONTREAL, QUEBEC and BOULDER, COLORADO--(Marketwire - October 25, 2007) - MethylGene Inc. (TSX: MYG) and Pharmion Corporation (NASDAQ: PHRM) today reported preliminary clinical data from the Companies’ MGCD0103 Phase I/II combination trial with Gemzar® (Trial 006). The data were presented in a poster session at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco on October 24th, 2007.
